Although FLT3 is not mutated in MM, elevated serum levels of FLT3L in RRMM patients [13] might result in increased activation of the downstream phosphorylation cascades, which could potentially be prevented by FLT3 inhibitors. Here, FLT3 is linked to Miyoshi myopathy.